BridgeBio Oncology
BBOT
67 hedge funds and large institutions have $514M invested in BridgeBio Oncology in 2026 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 20 increasing their positions, 11 reducing their positions, and 7 closing their positions.
229% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 7
82% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 11
26% more funds holding
Funds holding: 53 → 67 (+14)
1.08% less ownership
Funds ownership: 72.9% → 71.82% (-1.1%)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
32% less capital invested
Capital invested by funds: $756M → $514M (-$242M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Royce & Associates
New York
|
+$6.83M |
| 2 |
LCM
Laurion Capital Management
New York
|
+$4.91M |
| 3 |
ACM
Aisling Capital Management
New York
|
+$4.87M |
| 4 |
AC
Armistice Capital
New York
|
+$3.52M |
| 5 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
+$3.45M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Catalio Capital Management
New York
|
-$31.4M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
-$15M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$10.7M |
| 4 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$5.81M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$3.92M |
BBOT Hedge Fund Activity: Q1 2026 in Review
67 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in BridgeBio Oncology (BBOT) for Q1 2026, worth a combined $514M — down 32% from $756M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new BBOT positions and 7 closed out — a net gain of 16 holders — while 20 added to existing stakes and 11 trimmed.
The largest buyer was Royce & Associates, opening a new position worth an estimated $6.83M. The largest seller was Catalio Capital Management, exiting entirely with an estimated $31.4M sold.
- 67 institutional investors held BridgeBio Oncology (BBOT) as of Q1 2026, up from 53 in Q4 2025.
- Funds reported $514M of BridgeBio Oncology stock for Q1 2026, down 32% quarter-over-quarter.
- 23 funds opened new BridgeBio Oncology positions in Q1 2026 and 7 closed out, a net change of +16 holders.
- The largest BridgeBio Oncology buyer in Q1 2026 was Royce & Associates, an estimated $6.83M added.
- The largest BridgeBio Oncology seller in Q1 2026 was Catalio Capital Management, an estimated $31.4M sold.
Based on aggregated 13F filings for Q1 2026.